Amicus Therapeutics Files 8-K on Operations and Financials

Ticker: FOLD · Form: 8-K · Filed: Nov 6, 2024 · CIK: 1178879

Amicus Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyAmicus Therapeutics, Inc. (FOLD)
Form Type8-K
Filed DateNov 6, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: 8-k, financial-condition, operations

Related Tickers: FOLD

TL;DR

Amicus Therapeutics filed an 8-K on Nov 6, 2024, covering financial condition and results of operations.

AI Summary

On November 6, 2024, Amicus Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational updates were detailed in the provided excerpt.

Why It Matters

This filing indicates Amicus Therapeutics is providing updates on its financial performance and operational status to the SEC, which is crucial for investors to assess the company's health.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report for operational and financial updates, not indicating any immediate or significant risks.

Key Players & Entities

  • AMICUS THERAPEUTICS, INC. (company) — Registrant
  • November 6, 2024 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • 47 Hulfish Street, Princeton, New Jersey 08542 (address) — Principal Executive Offices

FAQ

What specific financial results or operational updates are detailed in this 8-K filing?

The provided excerpt of the 8-K filing does not detail specific financial results or operational updates; it only indicates that the report concerns 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'.

When was this 8-K report filed with the SEC?

This 8-K report was filed on November 6, 2024.

What is the exact name of the company filing this report?

The exact name of the company filing this report is AMICUS THERAPEUTICS, INC.

In which state was Amicus Therapeutics, Inc. incorporated?

Amicus Therapeutics, Inc. was incorporated in Delaware.

What is the principal executive office address for Amicus Therapeutics, Inc.?

The principal executive office address for Amicus Therapeutics, Inc. is 47 Hulfish Street, Princeton, New Jersey 08542.

Filing Stats: 557 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-11-06 07:01:15

Key Financial Figures

  • $0.01 — ich registered Common Stock Par Value $0.01 FOLD Nasdaq Indicate by check mar

Filing Documents

02 Results of Operations and Financial

Item 2.02 Results of Operations and Financial Condition. On November 6, 2024, Amicus Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fiscal quarter ended September 30, 2024. A copy of this press release is attached hereto as Exhibit 99.1. The Company will host a conference call and webcast on November 6, 2024 to discuss its second quarter results of operations. A copy of the conference call presentation materials is attached hereto as Exhibit 99.2. Both exhibits are incorporated herein by reference. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K and the Exhibits shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press Release dated November 6, 2024 99.2 November 6, 2024 Conference Call Presentation Materials 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Signature Page Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AMICUS THERAPEUTICS, INC. Date: November 6, 2024 By: /s/ Ellen S. Rosenberg Name: Ellen S. Rosenberg Title: Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.